In this phase I study we will characterize the safety, tolerability, maximum tolerated dose and dose-limiting toxicity of weekly bolus topotecan when administered in combination with two different dosing schedules of carboplatin. We will also evaluate any antitumor activity of these combination regimens.
Upon determination of eligibility, patients will be receive: * Topotecan + Carboplatin In order to determine the most appropriate dosing regimen to progress into future phase II trials, two different dosing schedules of topotecan and carboplatin will be utilized (ARM I and ARM II). Patients will be accrued to both treatment arms simultaneously.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Maximum tolerated dose
Dose limiting toxicity
All over response
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.